Global Stem Cell Partnering Terms and Agreements 2010-2022


The Global Stem Cell Partnering Terms and Agreements 2010-2022 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2022
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Stem Cell Partnering Terms and Agreements 2010-2022 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.


  • Trends in stem cell partnering 
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for stem cells


The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.


This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.


The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.


The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading Stem Cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.



Key benefits


Global Stem Cell Partnering Terms and Agreements 2010-2022 provides the reader with the following key benefits:


  • In-depth understanding of Stem Cell deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
  • Identify most active Stem Cell dealmakers since 2010
  • Insight into terms included in a Stem Cell partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Stem Cell Partnering Terms and Agreements 2010-2022 is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide.


Stem Cell Partnering Terms and Agreements includes:


  • Trends in Stem Cell dealmaking in the biopharma industry since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to Stem Cell contract documents
  • Leading Stem Cell deals by value since 2010
  • Most active Stem Cell dealmakers since 2010



In Global Stem Cell Partnering Terms and Agreements 2010-2022, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



The Global Stem Cell Partnering Terms and Agreements 2010-2022 report provides comprehensive access to available deals and contract documents for over 650 Stem Cell deals.


Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Stem Cell Partnering Terms and Agreements 2010-2022 provides the reader with the following key benefits:


  • In-depth understanding of stem cell deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual stem cell contracts entered into by leading biopharma companies
  • Identify most active stem cell dealmakers since 2010
  • Insight into terms included in a stem cell partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Stem Cell dealmaking


2.1. Introduction

2.2. Stem Cell partnering over the years

2.3. Most active Stem Cell dealmakers

2.4. Stem Cell partnering by deal type

2.5. Stem Cell partnering by therapy area

2.6. Deal terms for Stem Cell partnering

2.6.1 Stem Cell partnering headline values

2.6.2 Stem Cell deal upfront payments

2.6.3 Stem Cell deal milestone payments

2.6.4 Stem Cell royalty rates


Chapter 3 – Leading Stem Cell deals


3.1. Introduction

3.2. Top Stem Cell deals by value


Chapter 4 – Most active Stem Cell dealmakers


4.1. Introduction

4.2. Most active Stem Cell dealmakers

4.3. Most active Stem Cell partnering company profiles


Chapter 5 – Stem Cell contracts dealmaking directory


5.1. Introduction

5.2. Stem Cell contracts dealmaking directory


Chapter 6 – Stem Cell dealmaking by technology type




Appendix 1 – Stem Cell deals by company A-Z


Appendix 2 – Stem Cell deals by stage of development




Phase I

Phase II

Phase III





Appendix 3 – Stem Cell deals by deal type


Asset purchase


Bigpharma outlicensing


Collaborative R&D







Equity purchase



Joint venture





Material transfer





Spin out



Technology transfer




Appendix 4 – Stem Cell deals by therapy area


Appendix 5 – Deal type definitions


Appendix 6 – Further reading on dealmaking


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Stem Cell partnering since 2010

Figure 2: Active Stem Cell dealmaking activity since 2010

Figure 3: Stem Cell partnering by deal type since 2010

Figure 4: Stem Cell partnering by disease type since 2010

Figure 5: Stem Cell deals with a headline value

Figure 6: Stem Cell deals with an upfront value

Figure 7: Stem Cell deals with a milestone value

Figure 8: Stem Cell deals with a royalty rate value

Figure 9: Top Stem Cell deals by value since 2010

Figure 10: Most active Stem Cell dealmakers since 2010

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, Aastrom Biosciences, Abbott Laboratories, ABT Holding Company, Abu Dhabi Stem Cells Center, Accellta, Access BIO, Access Pharmaceuticals, ACEA Biosciences, Actinium Pharmaceuticals, ADIENNE Pharma & Biotech, Admedus, AdnaGen, Advanced BioScience Laboratories, Advanced Cell Technology, Aelan Cell Technologies, Affomix, AGC Asahi Glass, Ageless Regenerative, AgeX Therapeutics, Agilent Technologies, AiVita Biomedical, Akadeum Life Sciences, Akron Biotechnology, Albert Einstein College of Medicine, Alkem Laboratories, Allele Biotechnology and Pharmaceuticals, AlloSource, Alphatec Spine, ALS Therapy Development Institute, Ambry Genetics, Amedica, American CryoStem, American Society of Hematology, American Type Culture Collection (ATCC), Amgen, AnC Bio, Angel Biotechnology, Angioblast Systems, Angiocrine Bioscience, Angionetics, Angiostem, Anthony Nolan, Antitope, Apceth, Aratana Therapeutics, Arbor Biotechnologies, Ariana Pharma, Array Biopharma, Arteriocyte Medical Systems, Arthrex, Ascendance Biotechnology, Ascent Therapeutics, Astellas Pharma, Asterand Bioscience, Asterias Biotherapeutics, AstraZeneca, Athersys, ATMI LifeSciences, Australian Research Council, Autogenesis, AuxoCell Laboratories, Axcelead Drug Discovery Partners, Axiogenesis, AXM Pharma, AxoSim, Bachmann-Strauss Dystonia & Parkinson Foundation, Bakulev Center of Cardiovascular Surgery of Russian Academy of Sciences, Barbara Ann Karmanos Cancer Institute, Bassett Salon Solutions, Bayer Healthcare, Bayer Innovation, Bayer Schering Pharma, Bayer USA Foundation, Baylor Research Institute, BD Biosciences, Beckman Research Institute of City of Hope, Becton Dickinson, Beijing Cy-Tech, Beijing Genomics Institute (BGI), Beike Biotech, Beike Holdings, Berlin-Brandenburg Center for Regenerative Therapies, Be The Match BioTherapies, Beyond Type 1, Bill and Melinda Gates Foundation, Bio-Techne, BioBridge Global, BioCardia, Biocompatibles International, Biocrates, Biocrea, BioDlogics, Biogalenys, Biogen, BioHeart, Biokine Therapeutics, BioLamina, BioLife Solutions, BiolineRX, Biological Industries, Biomed, Biomedical Advanced Research and Development Authority, Biomerix, Biomodels, Bioneer, BioPontis Alliance, bioRASI, BioRestorative Therapies, Biosafe, BioSante Pharmaceuticals, Biostem US, Biotech Products Services & Research, BioTime Acquisition, BioTime Asia, Bluebird Bio, BlueRock Therapeutics, Boehringer Ingelheim, Bone Therapeutics, BrainStorm Cell Therapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Butler Schein Animal Health, Caladrius Biosciences, Calidi Biotherapeutics, California Institute for Regenerative Medicine, California State University, California Stem Cell, Calimmune, Canadian Institutes of Health Research, Canadian National Transplant Research Program, Capricor Therapeutics, CareDx, Case Western Reserve University, Case Western Reserve University School of Medicine, CASI Pharmaceuticals, Catalent, Cedars-Sinai Medical Center, CeeTox, Celera, Celgene, Cell2in, Cell Applications, Cellaria Biosciences, CellCap, Cell Care Therapeutics, Cell Culture Service, Cell Cure Neurosciences, Cellect Biotechnology, Cellectis, Cellectis Bioresearch, Cellectricon, Cellerix, Celling Biosciences, Cell Line Genetics, CellProThera, Celltex Therapeutics, Cell Therapy, Cell Therapy Catapult, Cellular Biomedicine, Cellular Dynamics International, Cellular Logistics, Cellzome, Celsis In Vitro Technologies, Celularity, Celulas Genetica, Censo Biotechnologies, Center for iPS Cells Research and Application, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Cephalon, Cesca Therapeutics, CFD Research, CHA Bio & Diostech, ChanTest, Charite-Universitatsmedizin, ChemDiv, Chemizon, Children's Hospital Boston, Children's Hospital of Orange County, Children's Research Institute, China Cord Blood, China Pharmaceuticals, China PharmaHub, China Southeast University, Chong Kun Dang, Cincinnati Children’s Hospital Medical Center, Cipla, Citius Pharmaceuticals, CIT Safety & Health Research Laboratories (CIT), City of Hope, Cleveland BioLabs, Cleveland Clinic, Cleveland Cord Blood Center, Clontech Laboratories, CNA Development, COARE Biotechnology, Cognate BioServices, Cohen-McNiece Foundation, Concessus, Connecticut Innovations, Connolly Healthcare, CORD:USE, Cord Blood America, Cord Blood Registry, Cordlife, CordVida, Coriell Institute for Medical Research, Cornell University, Corning, CPC Clinical Research, Creative Medical Technologies, CRISPR Therapeutics, CropLife America, Crown Bioscience, Cryo-Cell International, CryoPort, CSIRO, Curasan, CvergenX, Cynata Therapeutics, Cyntellect, Cystinosis Research Foundation, Cytomedix, Cytori Therapeutics, CYTOVIA Therapeutics, Cytovis, Dako, Dana-Farber Cancer Institute, DefiniGEN, Dendreon, Department of Defense, Department of Health and Human Services, DePuy, Dexterity, DiNonA, Dolomite, Domainex, Dow Chemical, Dow Corning, Duke University, DV Biologics, Ectycell, EdiGene, Eli Lilly, Elixirgen, Ellison Medical Foundation, EMD Millipore, Emerging Healthcare Solutions, Emory University, Entest BioMedical, EpiBone, Epistem, Eppendorf, ERS Genomics, Escape Therapeutics, ES Cell International, European Commission, European Union, Eutilogics, Evotec, ExCellThera, ExxonMobil, FarmaMondo Group, Fast Forward, Fate Therapeutics, Federal Ministry of Education and Research (BMBF), Fenwal, Florey Institute of Neuroscience and Mental Heath, Florica Therapeutics, Florida State University, Fluidigm, Fondazione San Raffaele, Fondazione Telethon, Food and Drug Administration (FDA), Fortis Healthcare, Fraunhofer Institute for Molecular Ecology (IME), Fred Hutchinson Cancer Research Center, Fujifilm, Fundacio Clinic, Fusion Antibodies, Fusion IP, Gamida Cell, GE Healthcare, GenCure, General Biotechnology, Generation Health, Generex Biotechnology, Genetic Technologies, Genetrix, Genext Medical Technology, Genome Diagnostics, genOway, GenScript ProBio, Gentium, GenVec, German Red Cross Blood Donor Service, Geron, Gladstone Institutes, GlaxoSmithKline, GliaMed, Global Alliance for Innovation in Neuroscience, Global Stem Cell Technology, Golden Helix, Golden Meditech, Government of Canada, Government of United Kingdom, Grandhope Biotech, Griffith University, Guangzhou Municipality Tianhe Nuoya Bio-engineering, Gulf Coast Pharmaceuticals, Hadasit Bioholdings, Hadasit Medical Research Services and Development, Hadassah Medical Center, Hadassah University, Haihe Laboratory of Cell Ecosystem, Hamad Bin Khalifa University, Hamilton Thorne, Hamner Institutes for Health Sciences, Harvard Medical School, Harvard Stem Cell Institute, Harvard University, Harvest Technologies, Healios K.K., HealthBanks Biotech, Healthpoint, Heartseed, Heat Biologics, HemaCare, HemispheRx Biopharma, Hemogenix, Hepregen, Heraeus, Histogen, Hoag Memorial Hospital Presbyterian, Hoffmann La Roche, Hong Kong Baptist University, Horizon Discovery, Huapont Pharma, Hubrecht Institute, Human BioMolecular Research Institute, Human Life CORD Japan, Human Longevity, HumanZyme, Humex Medical, Icon, iCo Therapeutics, ID Pharma, Ilika Technologies, Illumina, ILS, ImageIQ, ImmuneCyte Life Sciences, ImmuneRegen BioSciences, ImmunityBio, ImmunoCellular Therapeutics, Implant Therapeutics, Indiana University, Indian Immunological, Inform Genomics, Innovate UK, Innovation Australia Research and Development, Innovative Medicines Initiative (IMI), Insitro, Instem, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for Translational Oncology Research, Institute of Cancer Research, Institute Of Molecular Biotechnology, Integrated Biobank of Luxembourg, Intellia Therapeutics, IntelliCell BioSciences, Intercytex, International Stem Cell, Intrexon, Invitrx Therapeutics, InVivo Therapeutics, Ionis Pharmaceuticals, iPS Academia Japan, ISee3D, Israeli National Authority for Technological Innovation, Jadi Cell, Jain Foundation, Janssen Biotech, Japan Science and Technology Agency, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, Jian An Pharmaceuticals, Johns Hopkins University, Johnson & Johnson Innovation, Juvenile Diabetes Research Foundation, Keck School of Medicine of USC, KellBenx, Kempbio, Kensey Nash, Kerecis, Kiadis Pharma, Kinetic River, Kings College London, Kite Pharma, Kumamoto University, Kyoto Biken, Kyoto University, Lab21, Laboratorios Bago, Laboratory Corporation of America, LaCell, La Jolla Institute for Allergy & Immunology, La Jolla Pharmaceutical, Lee Moffitt Cancer Center, Lehigh University, Leiden University, Lentigen, Leona M and Harry B Helmsley Charitable Trust, Leukemia & Lymphoma Society, Lifeline Skin Care, LifeMap Sciences, LifeSouth Community Blood Centers, Life Technologies, Life Technologies Corporation, Lineage Cell Therapeutics, Longeveron, Lonza, Lorna Linda University, Loughborough University, Lucigen, Lupus Foundation of America (LFA), Macquarie University, Magenta Therapeutics, Magnum Cell Therapies, Maryland Stem Cell Research Fund, Maryland Technology Development Corporation, Massachusetts General Hospital, Matricel, Maxcyte, Mayo Clinic, McEwen Centre for Regenerative Medicine, McGill University, McKesson, McMaster University, MD Anderson Cancer Center, Medac, Medexus Pharmaceuticals, Medical College of Wisconsin, Medical Research Council, Medical Technology Enterprise Consortium, Medical University South Carolina, Medidata Solutions, Medistem, Memorial Sloan Kettering Cancer Center, Merck and Co, Merus, Mesoblast, Metagenomi, Metrion Biosciences, Michael J Fox Foundation, Midas Mediscience, Mill Creek Life Sciences, Miltenyi Biotec, Minerva Biotechnologies, Ministry of Industry and Trade of the Russian Federation, Miracle Babies, Miragen Therapeutics, Mirna Therapeutics, Mokshagundam Biotechnologies, Molecular Imaging Research, Molecular Response, Molecular Templates, Monash University, Montefiore Medical Center, Montreal Heart Institute, MorphoSys, MPI Research, Multiclonal Therapeutics, Munich Technical University, Murdoch Childrens Research Institute, Muscular Dystrophy Association, myTomorrows, Nanion, NanoCellect Biomedica, Nano Dimension, nanoRanch, Nanotope, Nanshan Memorial Medical Institute, NantKwest, Nanyang Technological University, Natera, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Regenerative Medicine, National Eye Institute, National Health and Medical Research Council, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Innovation, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institutes of Health, National Institutes of Health Center for Regenerative Medicine, National Psoriasis Foundation, National Research Council Industrial Research Assistance Program, National Science Foundation, National Stem Cell Foundation, National University of Ireland, Galway (NUI Galway), Ncardia, Nestle Health Science, Netherlands Government, NetScientific, NeuralStem, Neural Stem Cell Institute, Neuromics, Neusentis, Newcastle University, NHS Blood and Transplant, Nohla Therapeutics, Northwestern University, North West Fund, Novartis, Novellus Therapeutics, Novo Nordisk, Nuclea Biotechnologies, NuGene International, Numerate, NuPotential, NuVasive, Obagi Medical Products, Obatala Sciences, Ocata Therapeutics, OcellO, Octane Biotech, Ocumension Therapeutics, Omeros, OncoImmune, OncoMed Pharmaceuticals, OptoRobotix, Orbsen Therapeutics, Orchard Therapeutics, Oregon Health Sciences University, Organovo, Orgenesis, ORIG3N, Orla Protein Technologies, Orthocell, OrthoCyte, Orthopaedic Research and Education Foundation, Osiris Therapeutics, Oxford Biodynamics, PacificGMP, panCELLa, Paragon Bioservices, Parcell Laboratories, Parcell Spine, Pathways to Stem Cell Science, PAWS Pet Company, PerkinElmer, Pfizer, PGXL Technologies, PharmaCell, PharmaCyte Biotech, Pharming Group, Philogen, Pikamab, Pivotal Scientific, Pizzaro Hair Restoration Clinic, Plasticell, Platelet BioGenesis, Pluriomics, Pluristem Therapeutics, Pluristyx, Polyplus Transfection, Prasco Laboratories, Primera Bioscience Research, Princess Margaret Hospital, Pro-Cure Therapeutics, ProBioGen, Procella Therapeutics, Procognia, Procyon Technologies, Progenitor Cell Therapy, Progenteq, Promega, Promosome, ProSpec-Tany, Protein Genomics, Proteonomix, P T Kalbe Farma, Pulthera, Qiagen, Q Therapeutics, Quintiles, RainDance Technologies, Ramot at Tel Aviv University, R Biomedical, RecipharmCobra Biologics, Recopharma, Recordati, ReCyte Therapeutics, Regen BioPharma, Regenerative Sciences, Regenerex, Regenetech, Regeneus, Reinnervate, ReNeuron, Renovacare, RenovoCyte, Rensselaer Polytechnic Institute, ReproCell, Research Products Development Company, Response Genetics, RHEI Pharmaceuticals, RNL Bio, Roche, Roche Applied Science, Rockefeller University, Rockland Immunochemicals, Rohto Pharmaceutical, Romer Labs, Roslin Cellab, Roslin Cells, ROSLINCT, Roslin Institute, Royal Children’s Hospital, Royal College of Surgeons (Ireland), RS Medical, RST Biomedikal Sanayi, RTI Surgical, Rubicon Genomics, Rutgers University, RxBio, Salk Institute, Sana Biotechnology, SanBio, Sanford Burnham Institute, Sanford Consortium for Regenerative Medicine, Sangamo Therapeutics, Sankara Nethralaya, Sanofi, Sanofi-Aventis, San Raffaele Telethon Institute for Gene Therapy, SAVSU Technologies, Scaled Biolabs, Schepens Eye Research Institute, ScinoPharm Taiwan, SCM Pharma, ScreenCell, Scripps Genomic Medicine, Scripps Research Institute, SDIX, Selexis, SeouLin Bioscience, SeqWright, Seres Therapeutics, Service Francophone du Sang, Shanghai Cell Therapy Group, Shanghai Jia Fu Medical Apparatus, Sharp Edge Labs, Shenogen Pharma, Shoreline Biosciences, Shrink Chips, Shrink Nanotechnologies, Sigma-Aldrich, Sigma-Tau, Sigma Life Science, Sinopharm, SiriCell Technologies, Sirion Biotech, Sirius Genomics, Sirona Biochem, Sistemic, Sitoa, Small Business Innovation Research, Smartwise, Smith & Nephew, South Texas Blood & Tissue Center, Spectrum Pharmaceuticals, Spinogenix, Stanford University, Starr Foundation, Stellar Pharmaceuticals, Stematix, StemBioSys, Stem Cell & Regenerative Medicine International (SCRMI), Stem Cell Medicine, Stem Cell Network, StemCells, Stem Cells 21, StemCell Systems, Stemcell Technologies, Stem Cell Therapeutics, StemCyte, StemedicaAnC, Stemedica Asia, Stemedica Cell Technologies, Stemedica Internaional, StemExpress, StemGenesis, Stemina Biomarker Discovery, Stemlife, Stemlogix, Stemnion, StemoniX, Stempeutics, Steven M. Schwartzberg Memorial Fund, Streamline Health Solutions, Stryker, Suneva Medical, Superview Biotechnology, Swedish Orphan Biovitrum, SwitchGear Genomics, Synterys, Synthecon, System Biosciences, Taconic Biosciences, TaiGen Biotechnology, TaiRx, Takara Bio, Takeda Pharmaceutical, TAP Biosystems, Targazyme, Taxus Cardium Pharmaceuticals, Technology Strategy Board (UK), Technology University Dresden, Teijin, Temple University, Terumo Blood and Cell Technologies, TET Systems, Teva Pharmaceutical Industries, TFS International, The Automation Partnership, The Global Stem Cell and Regenerative Medicine Acceleration Center (GSRAC), The Hospital for Sick Children, The Marta and Owen Boris Foundaton, The New York Stem Cell Foundation, TheraBiologics, Therakine, Therapeutic Solutions International, The Regents of the University of California, ThermoGenesis, The UK Stem Cell Bank, Thomas Jefferson University, Thrive Bioscience, Tianhe Stem Cell Biotechnologies, TiGenix, Tissue Genesis, Tissue Regeneration Therapeutics (TRT), Tiziana Life Sciences, Transgenomic, Transposagen Biopharmaceuticals, Trestle Biotherapeutics, Trillium Therapeutics, Tri Phuoc, TTFactor, Tu Dresden, U CAN-CER VIVE Foundation, UCB, Unilever, University Ann & Robert H. Lurie Children’s Hospital, University Campus Suffolk, University City Science Center, University College London, University Health Network, University Hospitals Case Medical Center, University of Adelaide, University of Birmingham, University of Calgary, University of California, University of California, Davis, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cologne, University of Connecticut, University of Dundee, University of Edinburgh, University of Florida, University of Louisville, University of Maryland, University of Maryland Baltimore, University of Maryland School of Medicine, University of Massachusetts, University of Massachusetts, Amherst, University of Massachusetts Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ), University of Melbourne, University of Miami, University of Miami Miller School of Medicine, University of Michigan, University of Minnesota, University of Montreal Pharmacogenomics Centre, University of Notre of Dame, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Pittsburgh Medical Center, University of Queensland, University of Rochester Medical Center, University of Sheffield, University of South Carolina, University of Southern California, University of Sydney, University of Tokyo, University of Tubingen, University of Utah, University of Washington, University of Wisconsin-Madison, University of York, US Army Institute of Surgical Research (USAISR), USCN Life Science, US Government, US Spine, US Stem Cell Clinic, Valamed, Vascugen, Vatican, Vectalys, Veritas, Vertex Pharmaceuticals, Vet-Stem, ViaCord, ViaCyte, ViraCyte, Virdante Biophrmaceuticals, Viscofan BioEngineering, VistaGen Therapeutics, VitaThreads, Vitro Biopharma, Vitro Diagnostics, Vitrolife, Vivalis, Vivo Biosciences, Vor Biopharma, Waisman Biomanufacturing, Wake Forest University, WCTE, Weill Cornell Medical College, Wellcome Trust, Wellcome Trust Sanger Institute, Welsh Government, W L Gore, Worcester Polytechnic Institute (WPI), XGen Medical, Yale University, Yeda Research and Development Company, Yorkshire Cancer Research, Yumanity Therapeutics, Zhongyuan Union Stem Cell Bioengineering, ZyGEM

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.